Abstract:More than fifteen years after their discovery, IDH mutations remain as intriguing as ever. Three mutational hotspots are described in different cancers, including glioma, chondrosarcoma, or hematological diseases, resulting in single amino acid substitutions in two of the IDH genes (IDH1R132, IDH2R172 and IDH2R140). Wild-type IDH1/2 catalyze the conversion of isocitrate into α-ketoglutarate (α-KG), and their mutations confer neomorphic activity to this metabolic enzyme, reducing α-KG to 2-hydroxyglutarate (2-HG). 2-HG is a potent inhibitor of several dioxygenases that normally use α-KG as a cofactor. Among them is the ten-eleven translocation (TET) family, which catalyzes the hydroxylation of methylated cytosine bases in the DNA. Mutations in epigenetic regulators, such as IDH, are commonly found in hematological malignancies including myelodysplastic syndrome (MDS), acute myeloid leukemia (AML) and peripheral T cell lymphoma (PTCL), and especially angioimmunoblastic T cell lymphoma (AITL). Despite many advances, these hematologic diseases still have significant unmet medical needs, and require novel approaches to patient selection and therapy. IDH inhibitors are currently under investigation in MDS, AML and PTCL and have shown promise in early clinical trials for AML and MDS. However, not all IDH-mutant patients respond, and resistance frequently develops. Changes to epigenetic regulation and diversity driven by IDH1/2 mutations likely contribute to these effects, but our incomplete understanding of the underlying biology limits therapeutic intervention. Establishing the relationship between tumor genetics and human diseases in the context of IDH mutations is challenging. The distribution of the three hotspot mutations among the different pathologies is complex and not yet fully understood. An intriguing fact is that IDH2R140 mutation is exclusively found in myeloid malignancies. Furthermore, clinical data indicate that the co-mutational pattern of IDH1/2 mutations is associated differently in hematological disorders. For instance, IDH1/2 and TET2 mutations are essentially mutually exclusive in myeloid context but frequently co-occur in AITL, suggesting that their effects in specific cell types and disease contexts may differ. Understanding how IDH1/2 and TET2 mutations drive malignancy and why they cooperate differently in myeloid and lymphoid diseases can help distinguish common from specific mechanisms in myeloid and lymphoid compartments, revealing specific tumor cell vulnerabilities, which could be targeted to improve patient outcomes. The laboratory of Professor Mak has generated three strains of Idh knock-in mice, each bearing one of the three hotspot mutations and has assembled a multidisciplinary team in epigenetics and clinical investigation to explore their role and set the stage for further mechanistic insight into mutant IDH, both in myeloid or lymphoid contexts. 2-HG levels differ between the myeloid and lymphoid lineages of each strain and may explain the variations in the mutational spectrum associated with different cellular contexts. Even within the myeloid lineage, analyses of these three Idh-mutant mice suggest that these alleles produce phenotypes of varying severity, correlating with 2-HG levels, with Idh2R172 exhibiting the most severe phenotype. We showed that altered DNA and histone methylation; partially block hematopoietic cell differentiation at the hematopoietic stem cell/progenitor stage; resulting in a hematopoietic phenotype reminiscent of human MDS. Given the mutual exclusivity of IDH1/2 and TET2 mutations in myeloid neoplasms, it has been hypothesized that they converge on a common oncogenic pathway. However, in a first study, we demonstrated that mutant Idh1 impairs DNA repair via a mechanism independent of Tet2 at the stem cell stage. Then, in a second study, we showed that these alterations have distinct, and even opposite, effects on hematopoietic stem cells and progenitors. Epigenetic and single-cell transcriptomic analyses revealed that Idh2R172 and Tet2 mutations had diverging consequences. Our data argue against a simple equivalence of Idh1/2 and Tet2 mutations, and may help to explain some of the clinical differences between TET2- and IDH-mutant in a myeloid context. In PTCL, the neoplastic cells represent a minor part of the tumor, a truth that is even more pronounced in AITL, where the microenvironment frequently accounts for 90% of the tumoral mass. Using molecular and histological approaches, it has been shown that driving mutations, such as TET2, occur in hematopoietic stem cells, and are found in both malignant and non-malignant cells. On the other hand, others alterations, such as IDH2, occur in mature T cells, specifically in T follicular helper (TFH) cells, and are restrictive to malignant cells. Our team, in collaboration with a group of researchers led by Drs. Philippe Gaulard and François Lemonnier, -Abstract Truncated-

Mutant IDH1 Downregulates ATM and Alters DNA Repair and Sensitivity to DNA Damage Independent of TET2.

High IDH1 Expression is Associated with a Poor Prognosis in Cytogenetically Normal Acute Myeloid Leukemia.

Prognostic Significance of IDH1 and IDH2 Mutations in Older Patients with Primary Cytogenetically Normal Acute Myeloid Leukemia

IDH1/2 mutations in acute myeloid leukemia patients and risk of coronary artery disease and cardiac dysfunction—a retrospective propensity score analysis

Prognostic Value of Isocitrate Dehydrogenase Mutations in Myelodysplastic Syndromes: a Retrospective Cohort Study and Meta-Analysis.

Lysine Acetylation Restricts Mutant IDH2 Activity to Optimize Transformation in AML Cells.

[Relationship between clinical characteristics and myelodysplastic syndrome patients with isocitrate dehydrogenase gene mutations].

Prognostic Significance of IDH1 Mutations in Acute Myeloid Leukemia: a Meta-Analysis.

Abstract SY16-01: What IDH mouse models have taught us about hematological diseases, from leukemia to T cell lymphoma

Mutant IDH1 inhibition induces dsDNA sensing to activate tumor immunity

Abstract 2934: TET2 deficiency accelerates leukemogenesis in the NHD13 mouse model of MDS

Reductive TCA cycle catalyzed by wild-type IDH2 promotes acute myeloid leukemia and is a metabolic vulnerability for potential targeted therapy

Mitochondrial Metabolism Supports Resistance to IDH Mutant Inhibitors in Acute Myeloid Leukemia.

Additional mutations in IDH1/2-mutated patients with acute myeloid leukemia

IDH1 Mutation Enhances Catabolic Flexibility and Mitochondrial Dependencies to Favor Drug Resistance in Acute Myeloid Leukemia

Focal disruption of DNA methylation dynamics at enhancers in IDH-mutant AML cells

Targeted Inhibition of Mutant IDH2 in Leukemia Cells Induces Cellular Differentiation

The Non-Cell-autonomous Function of ID1 Promotes AML Progression Via ANGPTL7 from the Microenvironment.

Disabling Uncompetitive Inhibition of Oncogenic IDH Mutations Drives Acquired Resistance

Some Novel Features of IDH1-mutated Acute Myeloid Leukemia Revealed in Chinese Patients

Characteristics and prognostic impact of IDH mutations in AML: a COG, SWOG, and ECOG analysis